AMGN

Source: articles.moneycentral.msn.com --- 33 days ago
...

Source: articles.moneycentral.msn.com --- 38 days ago
Amgen and Wyeth release statement in response to FDA safety announcement; says both companies maintain ongoing safety surveillance programs worldwide Both AMGN and WYE notes that that FDA has ...

Source: www.prnewswire.com --- 14 days ago
...

Source: www.streetinsider.com --- 10 days ago
Visit StreetInsider.com at http://www.streetinsider.com/Management+Changes/Amgen+%28AMGN%29+Appoints+Francois+de+Carbonnel+to+the+Company%27s+Board/4041133.html for the full story. ...

Source: www.streetinsider.com --- 6 days ago
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Pressure+BioSciences+%28PBIO%29+Comments+on+Favorable+Data+Presented+by+Scientists+at+Amgen+%28AMGN%29/4052314.html for the full story. ...

Source: www.streetinsider.com --- 11 days ago
UPGRADES: Goldman Sachs upgrades Digital River Inc. (Nasdaq: DRIV) from Sell to Neutral. William Blair upgrades Amgen (Nasdaq: AMGN) from Market Perform to Outperform. Merrill Lynch upgrades BP (NYSE: BP) from Underperform to Neutral. For daily real-time Upgrades go to http://www.streetinsider.com/Upgrades DOWNGRADES: Morgan Stanley downgrades Las Vegas Sands (NYSE: LVS) from Overweight to Equalweight. Goldman Sachs downgrades Alcoa, Inc. (NYSE: AA) from Buy to Neutral. Calyon Securities downgrades Sun Microsystems (Nasdaq: JAVA) from Neutral to Reduce. Morgan Keegan downgrades Juniper Networks (Nasdaq: JNPR) from Outperform to Market Perform. For daily real-time Downgrades go to http://www.streetinsider.com/Downgrades NEW COVERAGE: Oppenheimer initiates coverage on Diana Shipping (NYSE: DSX) with an ...

Source: www.socialpicks.com --- 33 days ago
SELL rating on Amgen Inc ( AMGN ) Start Price:   $62.82 Start Date:   09/11/2008 ...

Source: www.topix.com --- 5 days ago
RDATE:01102008 Boston, MA -- Airspan Networks Inc. ; Amgen Inc., TheWallStreetLeader.com is part of Stock Profiler.US, LLC's News Division. ...

Source: www.topix.com --- 38 days ago
Market Pulse is pleased to announce the following stock picks. Bernard Schmitt of Market Pulse states, "These particular stocks should be closely watched due to existing fundamental and technical factors ... ...

Source: www.wangshappytrading.com --- 28 days ago
from MyHappyTrading.com (FREE Membership) by HappyTrading! ™ So, the market bounced today!  Last night, in my evening post, I said, “Although most sectors still look weak, we should see some bounces tomorrow.  Some of these commodity-related stocks have really taken a beating, and, could get some near-term bounces.” Metals, coals, energy stocks, fertilizers were all up today.  Yesterday’s big [...] ...

Source: www.gstock.com --- 16 days ago
GStock - Amgen Inc. (AMGN) ...

Source: articles.moneycentral.msn.com --- 13 days ago
Amgen Inc., (NASDAQ: AMGN) announced it has received a summary of preliminary results from the Cochrane Collaboration’s independent meta-analysis of patient-level data from previously conducted, ...

Source: articles.moneycentral.msn.com --- 10 days ago
Amgen (NASDAQ:AMGN) announced today that its Board of Directors has appointed François de Carbonnel to the Company's Board. Mr. de Carbonnel, 61, is a consultant and corporate financial advisor. He ...

Source: articles.moneycentral.msn.com --- 38 days ago
Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), issued a statement in response to the Food and Drug Administration (FDA) safety announcement regarding opportunistic ...

Source: articles.moneycentral.msn.com --- 29 days ago
Biovitrum AB (publ) (STO:BVT) and Amgen (NASDAQ:AMGN) announced today that they have entered into an agreement under which Biovitrum will acquire the marketed biologic therapeutic products ...

Source: articles.moneycentral.msn.com --- 27 days ago
Amgen (NASDAQ:AMGN) will participate in the Merrill Lynch Global Pharmaceutical, Biotech & Medical Devices Conference on Thursday, Sept. 18, 2008, at the Merrill Lynch Financial Centre in ...

Source: news.google.com --- 25 days ago
UPDATE:J&J Says Psoriasis Drug Is Superior To Amgen's Enbrel CNNMoney.com - 1 hour ago By Peter Loftus Johnson & Johnson (JNJ) said its experimental drug ustekinumab was more effective at treating the skin disease psoriasis than Amgen Inc.'s (AMGN) and Wyeth's (WYE) blockbuster drug Enbrel in a J&J-funded patient study. UPDATE 1-J&J psoriasis drug beats top-seller Enbrel in trial Reuters Psoriasis Drug from J&J Beats Enbrel in Study Wall Street Journal Blogs Bizjournals.com  - The Associated Press  - FierceBiotech  - Pharmalot all 89 news articles ...

Source: sanfrancisco.bizjournals.com --- 37 days ago
Cytokinetics Inc. started a third mid-stage clinical trial of a drug aimed at heart failure. (CYTK) (AMGN) ...

Source: www.businesswire.com --- 13 days ago
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Amgen Inc., (NASDAQ: AMGN) announced it has received a summary of preliminary results from the Cochrane Collaboration’s ...

Source: www.marketwire.com --- 29 days ago
STOCKHOLM, SWEDEN and THOUSAND OAKS, CA--(Marketwire - September 15, 2008) - Biovitrum AB (publ) (STO: BVT) and Amgen ( NASDAQ : AMGN ) announced today that they have entered into an agreement under which Biovitrum will acquire the marketed biologic therapeutic products Kepivance® (palifermin) and Stemgen® (ancestim) from Amgen, and will also obtain from Amgen a worldwide exclusive license to Kineret® (anakinra) for its current approved indication. The agreement includes an inventory of the three products at an undisclosed value. ...